VativoRx, LLC

01/23/2026

Rebate programs don’t usually fail in a steady state. They fail during change.

M&A, site expansion, vendor shifts, and staffing turnover create hidden risk most teams don’t plan for.

Edition 20 of The Rebate Report examines why rebates often fail during transitions and what resilient organizations do differently.

https://www.linkedin.com/pulse/why-rebates-break-during-transitions-vativorx-llc-cxp0e

01/09/2026

Specialty drug spend keeps rising, but the first thing to fail isn’t utilization or volume. It’s visibility.

In Edition 19 of The Rebate Report, we explore what breaks first when specialty spend accelerates, and why clarity, not reaction, defines resilience in 2026.

https://www.linkedin.com/pulse/what-breaks-first-when-specialty-drug-spend-accelerates-tpgje

01/07/2026

🩸 FDA update: Omisirge® is now approved to treat severe aplastic anemia in patients ages 6+ who don’t have a matching donor. It’s the first cell therapy approved for this condition and uses enhanced donated cord blood to help restore bone marrow function.

https://vativorx.com/pharmacy-bulletin-01-07-2026/

On Dec. 5, 2025, the US Food and Drug Administration (FDA) approved Gamida Cell’s Omisirge® (omidubicel-onlv) suspension for the treatment of severe aplastic anemia in patients six years and older following reduced intensity conditions and for whom a compatible donor is not available, marking the...

12/18/2025

🧬 New biosimilar approved! The FDA has approved Armlupeg™, a biosimilar to Neulasta®, to help cancer patients reduce infection risk during chemotherapy. It joins several existing options, increasing choice and competition in supportive cancer care.

https://vativorx.com/pharmacy-bulletin-12-18-2025/

On Nov. 28, 2025, the US Food and Drug Administration (FDA) approved Lupin’s biosimilar to Amgen’s Neulasta® (pegfilgrastim), Armlupeg™ (pegfilgrastim-unne) 6mg/0.6mL injection. It is indicated to decrease the risk of infections in patients receiving cancer drugs that interfere with the bone ...

12/16/2025

As the year wraps up, most healthcare finance teams are planning for 2026.
But before turning the page, one question matters:

Are all of your 2025 claims truly closed?

Edition 18 of The Rebate Report explores year-end housekeeping, limited lookback windows, and why early Q1 isn’t “too late”—but it may be the last opportunity.

https://www.linkedin.com/pulse/dont-leave-2025-open-year-end-housekeeping-checklist-healthcare-fp9ze

12/09/2025

⚠️ The FDA has added a boxed warning to Elevidys®, Sarepta’s gene therapy for Duchenne muscular dystrophy, after reports of fatal liver failure. Use is now limited to ambulatory patients age 4+. New liver and heart monitoring requirements apply.

https://vativorx.com/pharmacy-bulletin-12-09-2025/

On Nov. 14, 2025, the US Food and Drug Administration (FDA) updated labeling for Sarepta Therapeutics’ Elevidys® (delandistrogene moxeparvovec-rokl), an AAVrh74-based gene therapy for Duchenne muscular dystrophy (DMD), following reports of fatal cases of acute liver failure in non-ambulatory pati...

12/08/2025

💊 The FDA has approved the first generic version of Premarin® tablets for menopause symptom relief. This milestone expands access to treatment for hot flashes & vaginal atrophy.

https://vativorx.com/pharmacy-bulletin-12-08-2025/

On Nov. 13, 2025, Ingenus Pharmaceuticals announced that the US Food and Drug Administration (FDA) approved a generic version of Pfizer’s Premarin® (conjugated estrogens) tablets for the treatment of menopausal symptoms, including vasomotor symptoms (hot flashes) and vaginal atrophy.

12/02/2025

🧬 The FDA has approved Komzifti™, a first-in-class oral menin inhibitor for adults with relapsed or refractory AML harboring NPM1 mutations. This breakthrough expands treatment options for patients with limited therapies.

https://vativorx.com/pharmacy-bulletin-12-02-2025/

On Nov. 13, 2025, the US Food and Drug Administration (FDA) approved Komzifti™ (ziftomenib – Kura Oncology and Kyowa Kirin), a selective oral menin inhibitor, for the treatment of adults who have relapsed or refractory (R/R) acute myeloid leukemia (AML) harboring a susceptible nucleophosmin 1 (N...

11/25/2025

🩺 The FDA has approved Javadin™, the first clonidine oral solution for hypertension. This option helps patients who struggle with swallowing tablets, making blood pressure control easier and more accessible.

https://vativorx.com/pharmacy-bulletin-11-25-2025/

On Oct. 24, 2025, the US Food and Drug Administration (FDA) approved Javadin™ (clonidine hydrochloride – Azurity Pharmaceuticals), an oral solution formulation of clonidine for the treatment of hypertension. Clonidine, an alpha-2 adrenergic agonist available since the 1970s, lowers blood pressur...

11/24/2025

💊 The FDA has approved Kygevvi®, the first treatment for thymidine kinase 2 deficiency (TK2d), an ultra-rare genetic disorder that causes progressive muscle weakness and respiratory failure.

https://vativorx.com/pharmacy-bulletin-11-24-2025/

On Nov. 3, 2025, the US Food and Drug Administration (FDA) approved UCB’s Kygevvi® (doxecitine and doxribtimine) for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and children whose symptoms started when they were 12 years of age or younger.

11/21/2025

🧬 The FDA has expanded Revuforj®’s approval to include adults & children (1+) with relapsed/refractory AML with NPM1 Mutations, the first therapy for this subtype. Now also NCCN-recommended.

https://vativorx.com/pharmacy-bulletin-11-21-2025/

On Oct. 24, 2025, the FDA approved Syndax Pharmaceuticals’ Revuforj® (revumenib), an oral menin inhibitor, for the treatment of relapsed or refractory (R/R) acute myeloid leukemia (AML) in adult and pediatric patients aged one year and older with a susceptible nucleophosmin 1 (NPM1) mutation in w...

11/17/2025

Provider trust in PBMs is at its lowest point in 15 years, and hospitals are increasingly seeking more direct visibility into their specialty drug spend.

Edition 17 of The Rebate Report breaks down the latest PSG findings and why more organizations are turning toward independent oversight of rebate-eligible medical-benefit drugs.

https://www.linkedin.com/posts/vativorx-llc_therebatereport-vativorx-hospitalfinance-activity-7396261620747870208-fBUu?utm_source=social_share_send&utm_medium=member_desktop_web&rcm=ACoAAAFXBloBZBzOrhB_kt8c9ooq-NgFFQbJ4ls